ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 68 filers reported holding ADC THERAPEUTICS SA in Q3 2022. The put-call ratio across all filers is 2.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $315,117 | +10.3% | 146,566 | 0.0% | 0.00% | – |
| Q1 2023 | $285,804 | -3.0% | 146,566 | +88.5% | 0.00% | – |
| Q4 2022 | $294,654 | -22.5% | 77,745 | 0.0% | 0.00% | – |
| Q3 2022 | $380,173 | -37.2% | 77,745 | 0.0% | 0.00% | – |
| Q2 2022 | $605,634 | -36.4% | 77,745 | +20.7% | 0.00% | -100.0% |
| Q1 2022 | $951,862 | – | 64,402 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 5,402,041 | $4,845,631 | 1.54% |
| Sio Capital Management, LLC | 3,294,534 | $2,955,197 | 0.92% |
| Redmile Group, LLC | 14,178,045 | $12,717,706 | 0.60% |
| AlphaCentric Advisors LLC | 1,068,468 | $958,416 | 0.54% |
| Vantage Consulting Group Inc | 850,737 | $763,111 | 0.51% |
| Blue Owl Capital Holdings LP | 733,568 | $654,489 | 0.51% |
| Affinity Asset Advisors, LLC | 1,100,000 | $986,700 | 0.28% |
| Frazier Life Sciences Management, L.P. | 1,647,030 | $1,477,386 | 0.10% |
| Indie Asset Partners, LLC | 92,700 | $83,152 | 0.08% |
| GCM Grosvenor Holdings, LLC | 410,888 | $368,567 | 0.07% |